Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland

Neoplasma

Volumn 53, Issue 4, 2006, Pages 305-308

  Kwiatkowska, E ^a   Skasko, E ^a   Niwinska, A ^a   Wojciechowska Lacka, A ^b   Rachtan, J ^c   Molong, L ^c   Nowakowska, D ^a   Konopka, B ^a   Janiec Jankowska, A ^a   Paszko, Z ^a   Steffen, J ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Wielkopolska Cancer Center   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast cancer; CHEK2*1100delC mutation; Population differences

Indexed keywords

CHECKPOINT KINASE 2;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FAMILIAL CANCER; FAMILIAL INCIDENCE; FAMILY HISTORY; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; POLAND; TUMOR;

EID: 33746280277     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. BARTEK J, LUKAS J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
2. SODHAN, WILLIAMS R, MANGION J, BULLOCK S, YUILLE M et al. Screening hCHK2 for mutations. Science 2000; 289: 359a.
3. WU X, WEBSTER SR, CHEN J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001; 276: 2971-2974.
4. BELL DW, VARLEY JM, SZYDLO TE, KANG DH, WAHRER DC et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
5. MEIJERS-HEIJBOER H, VAN DEN OUWELAND A, KLIJN J, WASIELEWSKIM DE SNOO A et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics 2002; 31: 55-59.
6. VAHTERISTO P, BARTKOVA J, EEROLA H, SYRJAKOSKI K, OJALA S et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432-438.
7. CYBULSKI C, GORSKI B, HUZARSKI T, MASOJC B, MIERZEJEWSKIM et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-1135.
8. The CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74: 1175-1182.
9. CALIGO MA, AGATA S, ACETO G, CRUCIANELLI R, MANOUKIAN S et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mut 2004; 24: 100-101.
10. FRIEDRICHSEN DM, MALONE KE, DOODY DR, DALING JR, OSTRANDER EA. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young woman. Breast Cancer Res 2004; 6: 629-635.
11. KLEIBL Z, NOVOTNY J, BEZDICKOVA D, MALIK R, KLEIBLOVA P et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat 2005; 90: 165-167.
12. OFFIT K, PIERCE H, KIRCHHOFF T, KOLACHANA P, RAPAPORT B et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003; 4: 1.
13. OSORIO A, RODRÍGUEZ-LÓPEZ R, DÍEZ O, DE LA HOYA M, IGNACIO MARTINEZ J et al. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004; 108: 54-56.
14. SODHA N, HOULSTON R, WILLIAMS R, YUILLE MA, MANGION J et al. A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mut 2002; 19: 173-177.
15. MOSOR M, ZIOLKOWSKA I, NOWAK J. Population frequencies of heterozygous NBS1 657del5 mutation carriers in Great Poland (in polish). Polish Genetic Congress Gdansk 2004.
16. STEFFEN J, VARON R, MOSOR M, MANEVA G, MAURER M et al. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 2004; 111: 67-71.
17. VARON R, SEEMANOVA E, CHRZANOWSKA K, HNATEJKO O, PIEKUTOWSKA-ABRAMCZUK D et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 2000; 8: 900-902.
18. GORSKI B, JAKUBOWSKA A, HUZARSKI T, BYRSKI T, GRONWALD J et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110: 683-686.
19. KLUSKA A, WOJCIECHOWSKA-LACKA A, PIATKOWSKA M et al. Preliminary evaluation of the frequencies and types of BRCA1 germline mutations among patients with familial and sporadic breast and ovarian cancers from three regions of Poland (in Polish). IV-th Polish Confrence on Diagnosis and Treatment of Breast Cancer. Nowotwory J Oncol 2005; 55 Supl 2: 27 (abstract).
20. BROEKS A, DE WITTE L, NOOIJEN A, HUSEINOVIC A, KLIJN JG et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83: 91-93.